A former Pfizer Inc. scientist denied an allegation made by House Republicans that he conspired to delay the release of Covid ...

The House Judiciary Committee announced that it is investigating whether Pfizer intentionally delayed releasing COVID vaccine results to influence the 2020 presidential election, following ...

Back in March, the The Wall Street Journal first reported that U.S. prosecutors were looking into claims Pfizer delayed the release of its COVID-19 vaccine until after the 2020 election.

The release of COVID-19 vaccine results days after the 2020 election may have not been a "coincidence" -- and could have been part of an effort by senior Pfizer executives to "deliberately slow ...

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the ...

Pfizer’s announcement about the effectiveness of its Covid-19 vaccine came nearly a week after Election Day, but Pfizer CEO Albert Bourla has said the timing had nothing to do with politics.

The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at rival Pfizer, had told his GSK colleagues about the delay.

Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could put additional pressure on Pfizer to find growth from its non-COVID ...

Full coverage of the COVID-19 pandemic. Hours later, CDC Director, Dr. Rochelle Walensky, signed off on the recommendation. “We now recommend that all adolescents aged 12-17 years should receive ...

Upon authorization by the European Commission (EC), the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2 ...

According to that data, cases peaked around Jan. 1, when about 1.4% of emergency department patient visits resulted in a COVID-19 diagnosis, far less than a year ago, when the diagnosis rate was 3.4%.